EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma

Sarah Rohlfing, Dilyana Vladimirova, Stephanie Berger, Sylvia Bochum, Gabrijela Otmacic, Marlene Weiß, Bence Sipos, Saskia Biskup, Marion Klaumünzer, Uwe M Martens iD

The Oncologist · 10.04.2026 · 31 (5)

DOI: 10.1093/oncolo/oyag108 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Oncologist, online erschienen am 30.03.2026. Verfasst von Sarah Rohlfing und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Gastroenterology, Hemato-Oncology, Pneumonology, Infectiology, and Intensive Care Medicine, RKH Fürst-Stirum-Klinik Bruchsal, 76646, Germa…. Hauptthemen laut MEDLINE: Adenocarcinoma, Carcinoma, Pancreatic Ductal, Circulating Tumor DNA, Immunotherapy. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marianne & Teodor Dauenhauer Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer remains one of the most lethal malignancies, with limited integration of precision oncology into routine clinical care. We present a unique case of a RAS wild-type, MSI-H, TMB-H pancreatic ductal adenocarcinoma harboring a TPM3-NTRK1 fusion, monitored through 13 serial liquid biopsies over 3 years. Dynamic changes in NTRK1-fusion allele frequency, tumor mutational burden, and the emergence of an NTRK1 resistance mutation guided finely tuned, situation-adapted therapeutic adjustments: rapid disease control with targeted NTRK inhibition followed by durable remission under immune checkpoint blockade. This case highlights the power of comprehensive molecular profiling and high-frequency ctDNA monitoring to capture tumor evolution and minimal residual disease. Importantly, it further demonstrates how MRD-guided surveillance enables a precise balance between fast-acting targeted therapy and the sustained effects of immunotherapy, providing a blueprint for individualized, context-driven treatment strategies in rare molecular subtypes of pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaCarcinoma, Pancreatic DuctalCirculating Tumor DNAImmunotherapyNeoplasm, ResidualPancreatic NeoplasmsReceptor, trkAHumansMaleMiddle Aged

Stichwörter der Autor:innen

NTRK fusionPDACliquid biopsyminimal residual diseasetailored treatment

Substanzen

Circulating Tumor DNANTRK1 protein, humanReceptor, trkA

Autor:innen und Institutionen

  • Clinic for Gastroenterology, Hemato-Oncology, Pneumonology, Infectiology, and Intensive Care Medicine, RKH Fürst-Stirum-Klinik Bruchsal, 76646, Germany.
  • Department for Hematology, Oncology, and Palliative Medicine, SLK-Clinics Heilbronn GmbH, 74078, Germany.
  • Qualipath-Practice for Pathology and Molecular Pathology, Stuttgart, 70176, Germany.
  • Center for Human Genetics Tübingen, Tübingen, 72076, Germany.
  • MOLIT Institute for Personalized Medicine, Heilbronn, 74076, Germany.

ORCID-Profile: Uwe M Martens

Förderung

  • Marianne & Teodor Dauenhauer Stiftung

Zitieren

APA

Rohlfing, S., Vladimirova, D., Berger, S., Bochum, S., Otmacic, G., Weiß, M., Sipos, B., Biskup, S., Klaumünzer, M., & Martens, U. M. (2026). Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag108

Vancouver

Rohlfing S, Vladimirova D, Berger S, Bochum S, Otmacic G, Weiß M, et al. Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag108

BibTeX
@article{Rohlfing2026,
  author = {Rohlfing, Sarah and Vladimirova, Dilyana and Berger, Stephanie and Bochum, Sylvia and Otmacic, Gabrijela and Weiß, Marlene and Sipos, Bence and Biskup, Saskia and Klaumünzer, Marion and Martens, Uwe M},
  title = {Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {5},
  doi = {10.1093/oncolo/oyag108}
}
Kostenlos starten →